Co-Authors
This is a "connection" page, showing publications co-authored by Issam Awad and Romuald Girard.
Connection Strength
9.161
-
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
Score: 0.770
-
Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
Score: 0.604
-
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
Score: 0.562
-
Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease. J Neurosci Methods. 2016 09 15; 271:14-24.
Score: 0.558
-
Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64.
Score: 0.544
-
Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations. Transl Stroke Res. 2024 Jul 09.
Score: 0.244
-
Transcriptomic signatures of individual cell types in cerebral cavernous malformation. Cell Commun Signal. 2024 01 09; 22(1):23.
Score: 0.235
-
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling. Stroke. 2024 01; 55(1):31-39.
Score: 0.234
-
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome. Stroke. 2024 01; 55(1):22-30.
Score: 0.234
-
Corrigendum to "Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu" [J. Autoimmun. 113 (2020) 102469]. J Autoimmun. 2023 Nov; 140:103116.
Score: 0.230
-
Inflammatory Mechanisms in a Neurovascular Disease: Cerebral Cavernous Malformation. Brain Sci. 2023 Sep 17; 13(9).
Score: 0.230
-
Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling. medRxiv. 2023 Jun 05.
Score: 0.226
-
Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation. J Stroke Cerebrovasc Dis. 2023 Jul; 32(7):107167.
Score: 0.224
-
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans. ACS Pharmacol Transl Sci. 2022 May 13; 5(5):266-277.
Score: 0.209
-
Propranolol as therapy for cerebral cavernous malformations: a cautionary note. J Transl Med. 2022 04 05; 20(1):160.
Score: 0.208
-
Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 10 01; 131(19).
Score: 0.201
-
COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
Score: 0.200
-
Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 02 01; 131(3).
Score: 0.192
-
Biomarkers of cavernous angioma with symptomatic hemorrhage. JCI Insight. 2019 06 20; 4(12).
Score: 0.172
-
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery. 2019 06 01; 84(6):1157-1168.
Score: 0.171
-
Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes. JCI Insight. 2019 Feb 07; 4(3).
Score: 0.167
-
Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis. Neurosurgery. 2018 12 01; 83(6):1260-1268.
Score: 0.165
-
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
Score: 0.159
-
Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial. Neurosurgery. 2017 Nov 01; 81(5):860-866.
Score: 0.153
-
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging. 2018 04; 47(4):1133-1138.
Score: 0.151
-
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
Score: 0.144
-
B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. J Neuroimmune Pharmacol. 2016 06; 11(2):369-77.
Score: 0.138
-
Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. AJNR Am J Neuroradiol. 2016 Jul; 37(7):1209-15.
Score: 0.137
-
Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
Score: 0.129
-
Epigenetic regulation by polycomb repressive complex 1 promotes cerebral cavernous malformations. EMBO Mol Med. 2024 Nov; 16(11):2827-2855.
Score: 0.062
-
Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling. Arterioscler Thromb Vasc Biol. 2024 06; 44(6):1246-1264.
Score: 0.060
-
Pathologic features of brain hemorrhage after radiation treatment: case series with somatic mutation analysis. J Stroke Cerebrovasc Dis. 2024 Jul; 33(7):107699.
Score: 0.060
-
Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations. Nat Commun. 2023 11 02; 14(1):7009.
Score: 0.058
-
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Commun Med (Lond). 2023 Mar 03; 3(1):35.
Score: 0.055
-
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2023 08; 14(4):513-529.
Score: 0.053
-
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circ Res. 2022 04 15; 130(8):1204-1229.
Score: 0.052
-
Developmental venous anomalies are a genetic primer for cerebral cavernous malformations. Nat Cardiovasc Res. 2022 Mar; 1:246-252.
Score: 0.052
-
Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth. J Magn Reson Imaging. 2022 05; 55(5):1440-1449.
Score: 0.050
-
Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. J Clin Invest. 2021 07 01; 131(13).
Score: 0.049
-
Cerebral Cavernous Malformation: From Mechanism to Therapy. Circ Res. 2021 06 25; 129(1):195-215.
Score: 0.049
-
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. J Cereb Blood Flow Metab. 2021 11; 41(11):2944-2956.
Score: 0.049
-
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
Score: 0.049
-
Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery. 2021 04 15; 88(5):961-970.
Score: 0.049
-
Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. J Exp Med. 2020 10 05; 217(10).
Score: 0.047
-
Novel Murine Models of Cerebral Cavernous Malformations. Angiogenesis. 2020 11; 23(4):651-666.
Score: 0.046
-
Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. 2020 10; 42(5):1351-1363.
Score: 0.046
-
Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nat Commun. 2020 05 27; 11(1):2659.
Score: 0.046
-
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. J Autoimmun. 2020 09; 113:102469.
Score: 0.046
-
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2021 03 01; 134(3):1147-1154.
Score: 0.045
-
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurg. 2020 Apr; 136:7-11.
Score: 0.045
-
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
Score: 0.044
-
Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med. 2019 11 27; 11(520).
Score: 0.044
-
Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites. J Magn Reson Imaging. 2020 04; 51(4):1192-1199.
Score: 0.044
-
A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. Transl Stroke Res. 2020 06; 11(3):365-376.
Score: 0.043
-
Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathol Commun. 2019 08 19; 7(1):132.
Score: 0.043
-
A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasis. Nat Commun. 2019 04 17; 10(1):1791.
Score: 0.042
-
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. 2019 04 01; 84(4):954-964.
Score: 0.042
-
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
Score: 0.042
-
Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. 2019 01 17; 133(3):193-204.
Score: 0.041
-
Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest. 2019 03; 99(3):319-330.
Score: 0.040
-
Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. J Exp Med. 2017 Nov 06; 214(11):3331-3346.
Score: 0.038
-
Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017 05 18; 545(7654):305-310.
Score: 0.037